Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.53 |
| ▸ | CES1 | P23141 | 2/20 | 0.53 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CHRNG | P07510 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CHRND | Q07001 | 1/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.36 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17219429 | 0.80 | S1PR3 (0.44) | CES2CES1KCNQ3KCNQ2CYP11B1 | |
| SCHEMBL28766354 | 0.80 | GABRA1 (0.35) | CES2CES1RAB9AMEN1KMT2A | |
| SCHEMBL28827436 | 0.79 | CES2 (0.48) | CES2CES1RAB9AMEN1KMT2A | |
| SCHEMBL29200432 | 0.76 | CES2 (0.55) | CES2CES1PLA2G7RAB9AMEN1 | |
| SCHEMBL28396264 | 0.76 | L3MBTL1 (0.41) | CES2CES1MEN1KMT2A | |
| SCHEMBL18762041 | 0.75 | GABRA1 (0.32) | — | |
| SCHEMBL22778005 | 0.75 | PLG (0.37) | MEN1KMT2ANPC1 | |
| SCHEMBL28456387 | 0.75 | CES2 (0.48) | CES2CES1RAB9ANPC1 | |
| SCHEMBL28478142 | 0.73 | CES2 (0.55) | CES2CES1RAB9AMEN1KMT2A | |
| SCHEMBL17219570 | 0.73 | CES2 (0.55) | CES2CES1RAB9ATAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380346-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | CRYSTALGENOMICS, INC. (KR) | 2022-12-01 | — | — | US | disclosed |
| EP-3428161-B1 | 2,3-DIHYDRO-ISOINDOLE-1-ONE DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | CRYSTALGENOMICS INC (KR) | 2022-09-07 | — | — | EP | disclosed |
| US-11230539-B2 | 2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same | CRYSTALGENOMICS, INC. (KR) | 2022-01-25 | — | — | US | disclosed |
| US-20210009565-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ONE DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | CRYSTALGENOMICS, INC. (KR) | 2021-01-14 | — | — | US | disclosed |
| EP-3428161-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Crystalgenomics, Inc. (KR) | 2019-01-16 | — | — | EP | disclosed |
| EP-2940014-B1 | 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | CRYSTALGENOMICS INC (KR) | 2018-09-26 | — | — | EP | disclosed |
| US-9758508-B2 | 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same | CRYSTALGENOMICS, INC. (KR) | 2017-09-12 | — | — | US | disclosed |
| US-20150336934-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | CRYSTALGENOMICS, INC. (KR) | 2015-11-26 | — | — | US | disclosed |
| EP-2940014-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Crystalgenomics, Inc. (KR) | 2015-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230539-B2 | 2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same | BTK, BRSK2, LCK | CES2 3908/4885CES1 1286/4885PLA2G7 1224/4885 |
| US-20210009565-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ONE DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | BTK, BRSK2, LCK | CES2 3908/4885CES1 1286/4885PLA2G7 1224/4885 |
| US-20150336934-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | BTK, LCK, BRSK2 | CES2 3546/4885CES1 1366/4885PLA2G7 833/4885 |
| US-20220380346-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | BTK, LCK, BRSK2 | CES2 3546/4885CES1 1366/4885PLA2G7 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.